MAPS, the Multidisciplinary Association for Psychedelic Studies, was started in 1986 by Rock Doblin. This is a nonprofit organization with the goal of raising awareness and improving understanding of psychedelic drugs and substances. Even though the group has focused on a wide variety of drugs over the years, its main focus has been MDMA. Specifically, the group has advocated for the use of MDMA in the treatment of depression. The group received approval from the FDA to initiate phase 3 clinical trials in 2016, and the FDA eventually designated MDMA as a breakthrough treatment option for those who suffer from PTSD. The group also sponsors a wide variety of other research studies that focus on other psychedelic drugs as well.